## **Special Issue**

# Unique Perspectives in Cancer Signaling

## Message from the Guest Editor

We are pleased to introduce a Special Issue on cancer signaling with a focus on unique, interdisciplinary perspectives for investigating key pathways that drive cancer initiation and progression. These perspectives can entail novel technological-computational implementations, translational-clinical-level applications, or even epidemiological enhancements of basic science understandings. Across these diverse inquiries, this edition on "Cancer Signaling" aims to define nuanced contexts surrounding oncogenic signaling for the development of therapeutic and preventive strategies against various cancers. Reviews are expected to focus on specific disease types or signaling pathways through a multidisciplinary lens. Original research articles with a focus along these scopes will also be considered.

## **Guest Editor**

Prof. Dr. Peiwen Fei

- 1. Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA
- 2. Graduate Program of Molecular Biosciences and Bioengineering, University of Hawaii, Honolulu, HI 96813, USA

## Deadline for manuscript submissions

closed (15 September 2024)



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/135538

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

